** Shares of Neurizon Therapeutics fall 26.5% to A$0.125, their lowest level since Jan. 15, 2024
** Stock falls as much as 29.4% in its biggest intraday pct drop since early September 2020
** Biotech firm receives notification from the U.S. FDA that its investigational new drug $(IND.AU)$ application for NUZ-001 to treat amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, has been put under clinical hold
** IND application is a request for authorisation to administer experimental drugs to humans
** Co says FDA has outlined certain concerns over sufficiency of information to assess application
** More than 2.9 mln shares change hands, 7.1 times the 30-day avg
** Neurizon down 26.5% YTD, including current session's moves
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。